TMJ 'dysfunction' - Health implications

Within this forum, you will discover valuable insights on how a 'dysfunctional' jaw, dental arch anomalies, and various body asymmetries can contribute to illness from a unique perspective. This is your go-to resource for finding effective solutions and achieving lasting relief.
It is currently Thu, 28 Mar 2024, 10:26 pm

All times are UTC [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
PostPosted: Fri, 12 Apr 2013, 12:44 pm 
Offline

Joined: Sun, 30 Sep 2012, 8:58 pm
Posts: 44
The University of Buffalo, New York has issued a press release reporting the results of their 'landmark pilot study of Liberation Treatment' and has stated that 'correcting CCSVI with venous angioplasty was of no value for treating MS."

They also released a YouTube video which claims that it may be 'potentially harmful' and advises 'caution strongly agaist the general acceptance of this invasive procedure for MS patients'.

In response Ashton Embry writes:

The Actual Data from PREMiSe Do Not Support the Highly Publicized, Anti-CCSVI Claims and Warnings of the University of Buffalo Researchers.

Ashton Embry, DIRECT-MS, April, 2013

Quick Summary

"The actual data from the PREMiSe Trial do not support the highly publicized claim that CCSVI correction by angioplasty is not of value for MS and may worsen disease activity. In sharp contrast, the data suggests that CCSVI correction may well be of substantial value for MS. The misleading claims made by University of Buffalo researchers are based on irrelevant data from the failed Phase 2 portion of the trial in which no one had their CCSVI corrected. The anti-CCSVI bias and baseless claims may be explained by the conflicts of interest."

Executive Summary
"University of Buffalo (UB) MS researchers put out a press release and Youtube video with claims that the Phase 2 portion (controlled, randomized and double blind) of their PREMiSe clinical trial demonstrated that CCSVI correction (restoration of >75% venous blood flow from the brain) by means of venous angioplasty, was not of value for MS and was possibly harmful.

An inspection of the PREMiSe data on the poster presented by UB researchers at the recent AAN convention in San Diego reveals the following
1) All the subjects in the open label, Phase 1 portion of the PREMiSe trial had their CCSVI was corrected (>75% blood flow restored by venous angioplasty). They had very good clinical results over the 6 months with no relapses and only 2 new lesions among the ten subjects.
2) The controlled and blinded Phase 2 portion of the PREMiSe trial was a failure because those receiving angioplasty did not have their CCSVI corrected (i.e. they did not have their blood flow restored to >75%)."

Read the full report here http:http://www.direct-ms.org/sites/default/files/Embry%20Premise%20Evaluation%20April%202013.pdf


Share on FacebookShare on TwitterShare on TuentiShare on SonicoShare on FriendFeedShare on OrkutShare on DiggShare on MySpaceShare on DeliciousShare on TechnoratiShare on TumblrShare on Google+
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC [ DST ]


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Rules of the BoardThe teamDelete all board cookies
cron
Disclaimer: Please read our Disclaimer of warranties and limitation of liability
Also see information on Intellectual Property Rights
Before posting, please read our Board Rules
Powered by phpBB® Forum Software © phpBB Group